Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (NCT03836040)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Who can join: Review the eligibility criteria below.
Location: Paradigm Clinical Research Center Inc — San Diego, California
Age range: 6 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (119 Sites)
Showing the first 25 of 119 sites.
- Paradigm Clinical Research Center Inc — San Diego, California
- Childrens Hospital Colorado — Aurora, Colorado
- Colorado Springs Neurological Associates — Colorado Springs, Colorado
- New England Institute for Clinical Research — Stamford, Connecticut
- Childrens National Health System — Washington D.C., District of Columbia
- Northwest Florida Clinical Research Group Limited Liability Company — Gulf Breeze, Florida
- Nicklaus Childrens Hospital — Miami, Florida
- Pediatric Epilepsy and Neurology Specialists — Tampa, Florida
- TrueBlue Clinical Research — Tampa, Florida
- Premiere Research Institute — West Palm Beach, Florida
- Rare Disease Research Center Pediatrics — Atlanta, Georgia
- CenExel iResearch, LLC — Savannah, Georgia
- Northwestern University — Chicago, Illinois
- Chicago Headache Center and Research Institute — Chicago, Illinois
- Josephson Wallack Munshower Neurology — Indianapolis, Indiana
- University of Maryland, Baltimore — Baltimore, Maryland
- New England Regional Headache Center Inc — Worcester, Massachusetts
- Michigan Head Pain and Neurological Institute — Ann Arbor, Michigan
- Clinical Research Institute Inc — Minneapolis, Minnesota
- Childrens Mercy Hospital and Clinics — Kansas City, Missouri
- Mercy Research — St Louis, Missouri
- Velocity Clinical Research, Inc — Grand Island, Nebraska
- Dent Neurosciences Research Center — Amherst, New York
- Modern Migraine MD — New York, New York
- Columbia University Irving Medical Center — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Migraine
- A Study of Wearable Devices to Predict Migraines — Rochester, Minnesota
- Treatment for Migraine and Mood — The Bronx, New York
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Birmingham, Alabama
- A Study to Evaluate White Matter Hyperintensities in Migraine — Phoenix, Arizona
- Migraine Manager (R01) — Cincinnati, Ohio
- Nerivio Efficacy Under High-Frequency Use — Bridgewater, New Jersey
Explore by condition: All Migraine clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.